您的位置 首页 农业百科

India’s Symbiotec Pharmalabs to Produce Precision-Fermented Protein for EU Partner in 10-Year Deal

Indian biotech firm Symbiotec Pharmalabs has signed a 10-year deal to serve as a contract manufacturer for a European company’s precision-fermented protein.

Shoring up India’s biomanufacturing prowess, Symbiotec Pharmalabs has expanded its contract manufacturing services for a European innovator in alternative proteins.

The biotech firm has signed a 10-year take-or-pay agreement with an unnamed European partner to produce its precision-fermented protein at its biomanufacturing campus in Ujjain.

The site is equipped with four 100,000-litre fermentation tanks, modular downstream processing capacity, and integrated quality assurance and quality control capabilities.

While production will begin at the existing facility, a new dedicated plant with several hundred thousand litres of fermentation capacity is set to follow, with contracted expansion options reserved for the European firm to take the programme into millions of litres.

Leveraging pharma expertise to address precision fermentation bottlenecks

India’s Symbiotec Pharmalabs to Produce Precision-Fermented Protein for EU Partner in 10-Year Deal
Courtesy: Symbiotec Pharmalabs

Precision fermentation involves inserting specific DNA into microbes to instruct them to produce desired molecules when fermented. The process can engineer microorganisms to manufacture proteins that are otherwise derived from animals, like whey, casein or ovalbumin.

The technology faces production and cost bottlenecks that need to be addressed, alongside the need to meet high-quality standards. Both factors are crucial for widespread adoption, but they usually pull in opposite directions, according to Symbiotec.

To solve this challenge, the firm leverages its quality systems as a pharmaceutical manufacturer and a long record of building and running its own fermentation plants at scale.

The R&D-driven pharmaceutical and biotech company has been around for over three decades, and serves over 200 customers in more than 40 countries across three verticals: active pharmaceutical ingredients, contract development and manufacturing services, and complex injectables.

These capabilities are supported by four manufacturing facilities in Madhya Pradesh, India, which have approvals from the US Food and Drug Administration, Japan’s Pharmaceuticals and Medical Devices Agency, and other global regulators, as well as Good Manufacturing Practices (GMP) clearance from the EU and WHO.

“Biotechnology is fundamentally changing how everyday products are made. Our planet needs cleaner, greener ways to produce essentials, and we are glad to see the industry moving in that direction,” said Symbiotec founder and managing director Anil Satwani.

“This fermentation-derived protein marks a major milestone in creating the clean, nutritious alternatives that consumers increasingly seek. We are well positioned to serve the alternative protein, human nutrition, and industrial bioproducts sectors,” he added.

India’s biomanufacturing sector proliferates

India’s Symbiotec Pharmalabs to Produce Precision-Fermented Protein for EU Partner in 10-Year Deal
Courtesy: Symbiotec Pharmalabs

The contract manufacturing partnership aligns with India’s BioE3 strategy, which focuses on accelerating tech development and commercialisation by setting up biomanufacturing hubs and biofoundries across the country.

The government has also published a roadmap to boost the national bioeconomy sector, with a target value of $2.6T by 2047. Within this, it plans to more than triple the value of the biotech sector, from $195B today to $691B in 2035, underlining bioindustrials – which include alternative proteins, enzymes, and food-grade media – as the segment with the largest potential.

It’s why biomanufacturing facilities and research hubs are cropping up nationwide. Bengaluru is home to the Centre for Smart Protein and Sustainable Material Innovation (an incubation hub) and the Alternative Proteins Innovation Center (a scale-up facility). And Hyderabad hosts the National Institute of Animal Biotechnology, an animal stem cell biobank.

In March, India formally launched the BIRAC-BioNest Incubation Centre in Mysore to help startups advance their research and achieve commercial viability for technologies like precision fermentation and CRISPR. A month later, the foundation stone was laid for an upcoming ₹42 crore ($4.5M) BioFoundry Centre to bridge the gap between lab research and industrial application of alternative proteins.

The private sector is building on this. This year, Swiss startup Planetary signed an exclusive partnership with Dharmpur Bio Organics to bring mycoprotein production to one of the latter’s sugar mills in India, while local firm PreferCo teamed up with German biotech giant Glatt to launch a precision fermentation scale-up centre in Hyderabad.

Meanwhile, Brevel and The Wave Group have teamed up to build an illuminated fermentation facility for microalgae proteins and ingredients in Uttar Pradesh, and Herbalife and the Indian Institute of Technology have opened a plant cell fermentation centre at the latter’s campus.

热门文章

发表回复

您的邮箱地址不会被公开。 必填项已用 * 标注